The Medical Briefing Nephrology
Telitacicept in IgA nephropathy, sodium and blood pressure, SGLT2 inhibitors (SMART-C), creatinine and cystatin C
Retrospective no. 7/12
The essentials in four articles
■ Glomerular disease
318 patients, 72 centers: urine protein/creatinine ratio −58.9% with telitacicept vs −8.8% with placebo at 39 weeks, GFR −1.0% vs −7.7%, serious events 2.5% vs 8.2%.
■ Clinical nephrology
Dose–response meta-analysis of 43 trials (1,759 patients): for −40 mmol/day of sodium (≈ 2.4 g of salt), systolic BP −4.5 mmHg in CKD, −2.3 mmHg in hypertension, almost no effect in normotensives; linear relationship, no threshold.
■ CKD and dialysis
SMART-C, 8 trials (58,816 participants): CKD progression −35% in people with diabetes and −26% in those without, AKI −23 to −28%, benefits consistent regardless of albuminuria level.
■ CKD and dialysis
23 cohorts (821,327 participants): a discordance of at least 30% between creatinine- and cystatin C-based GFR affects 11% of outpatients and 35% of inpatients, and is associated with higher mortality (HR 1.69).